(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/115986 A1

(51) International Patent Classification[7]: C07D 213/81, 241/24, A61K 31/44, 31/4965

(21) International Application Number: PCT/SE2005/000753

(22) International Filing Date: 20 May 2005 (20.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0401345-4 25 May 2004 (25.05.2004) SE

(71) Applicant *(for all designated States except US)*: **AstraZeneca AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **AMIN, Kosrat** [SE/SE]; AstraZeneca R & D Mönlndal, S-431 83 Mölndal (SE). **BRODDEFALK, Johan** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **DESFOSSES, Helene** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **EVERTSSON, Emma** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LIU, Ziping** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **MILBURN, Claire** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **NILSSON, Karolina** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **TREMBLAY, Maxime** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **WEI, Zhong-yong** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **YANG, Hua** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]


(54) Title: THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD




I



IA



IB



IC

(57) Abstract: Compounds of formulas I, IA, and IB or IC or pharmaceutically acceptable salts thereof: wherein A, A^1, A^2, A^3, A^4, R^2, R^3, R^4 and n are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

WO 2005/115986 A1

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.